Eleanor Wong

Eleanor Wong

Auto-generated profile, based on publicly available information

Eleanor Wong

Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
EWEleanor Wong
Eleanor Wong
NBNicolas Bertin
Nicolas Bertin
MHMaxime Hebrard
Maxime Hebrard
RTRoberto Tirado-Magallanes
Roberto Tirado-Magallanes
CBClaire Bellis
Claire Bellis
DKDimitar Kenanov
Dimitar Kenanov

5 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCSock Hoai Chan
Sock Hoai Chan
YBYasmin Bylstra
Yasmin Bylstra
JTJing Xian Teo
Jing Xian Teo
JKJyn Ling Kuan
Jyn Ling Kuan
NBNicolas Bertin
Nicolas Bertin
WLWeng Khong Lim
Weng Khong Lim
Asian populations are under-represented in human genomics research. Here, we characterize clinically significant genetic variation in 9051 genomes representing East Asian, South Asian, and severely under-represented Austronesian-speaking Southeast Asian ancestries. We observe disparate genetic risk burden attributable to ancestry-specific recurrent variants and identify individuals with variants specific to ancestries discordant to their self-reported ethnicity, mostly due to cryptic admixture. About 27% of severe recessive disorder genes with appreciable carrier frequencies in Asians are missed by carrier screening panels, and we estimate 0.5% Asian couples at-risk of having an affected child. Prevalence of medically-actionable variant carriers is 3.4% and a further 1.6% harbour variants with potential for pathogenic classification upon additional clinical/experimental evidence. We profile 23 pharmacogenes with high-confidence gene-drug associations and find 22.4% of Asians at-risk of Centers for Disease Control and Prevention Tier 1 genetic conditions concurrently harbour pharmacogenetic variants with actionable phenotypes, highlighting the benefits of pre-emptive pharmacogenomics. Our findings illuminate the diversity in genetic disease epidemiology and opportunities for precision medicine for a large, diverse Asian population.

13 May 2025 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
NSNilanjana Sadhu
Nilanjana Sadhu
RDRinkoo Dalan
Rinkoo Dalan
PJPritesh R. Jain
Pritesh R. Jain
CLChang Jie Mick Lee
Chang Jie Mick Lee
LPLeroy Sivappiragasam Pakkiri
Leroy Sivappiragasam Pakkiri
JCJohn C. Chambers
John C. Chambers

15 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
CBClaire Bellis
Claire Bellis
GKGabriel Kolle
Gabriel Kolle
JYJacklyn Yong
Jacklyn Yong
MHMaxime Hebrard
Maxime Hebrard
BLBitong Clarabelle Alexandrine Lin
Bitong Clarabelle Alexandrine Lin
PTPatrick Tan
Patrick Tan
The whole-of-nation National Precision Medicine (NPM) programme in Singapore aims to integrate a genomics backbone into standard healthcare. Phase II recently completed the sequencing of 102,202 genomes from the diverse Asian population of Singapore, generating the PRECISE-SG100K dataset. The scaling from the pilot SG10K_Health phase to national production scale demanded a central shift: from earlier generation workflows to an integrated, industrial grade “ Genomic Engine ”. The initiative was co-developed under a public-private partnership model. Our Genomic Engine was designed with an automation-first approach, as a modular platform linking a purpose-built, centralized biospecimen processing and DNA extraction facility (EXTRACT Lab), a high-throughput sequencing operation (Illumina Data Generation Infrastructure, IDGI), with the cloud-native analytics (GRIDS) running on a fully integrated PRECISE Sample Tracking System (STS). Here we describe the key design features of our Genomic Engine. Highlighting the Stress Test phase where the automated DNA extraction yields failed to meet expectations. We share the operational adjustments which were implemented to stabilize production and resulted in a three-fold reduction in sample triage due to improved DNA recovery. Without establishing the operational guardrails during the Stress Test, the Engine would not have reached a steady-state production evidenced by >3,000 genomes per month, median turnaround time 11 days, 99.6% operational success, within in six months. This framework offers a practical blueprint for other population-scale initiatives seeking to bridge the gap between scientific piloting and industrial delivery.

29 July 2026 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SSShih Wee Seow
Shih Wee Seow
TMTheresia Mina
Theresia Mina
MHMaxime Hebrard
Maxime Hebrard
NSNilanjana Sadhu
Nilanjana Sadhu
CBClaire Bellis
Claire Bellis
PTPatrick Tan
Patrick Tan

18 August 2026 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SSShih Wee Seow
Shih Wee Seow
TMTheresia Mina
Theresia Mina
MHMaxime Hebrard
Maxime Hebrard
NSNilanjana Sadhu
Nilanjana Sadhu
CBClaire Bellis
Claire Bellis
PTPatrick Tan
Patrick Tan